(2012) investigated the kinetics of urinary FB1: in a study involving a single individual, the authors analysed all urine excreted and determined an excretion rate of 0.78% for FB1
Adrenal Insufficiency
Visit our Foundayo page for full details on dosing, trial results, and side effects
Advertisement Large retrospective analysis may prompt prospective studies How to talk about lifetime risk, treatment goals, Lp(a) testing, statin skepticism and more Robust signal from observational study raises prospect of a long-sought medical therapy Retrospective analysis finds lower mortality rates, fewer hospital visits among patients with Type 1 diabetes using GLP-1 Therapies Study shows significantly reduced risk of mortality and disease complications in patients receiving GLP-1 agonists Observational evidence of neuroprotection with GLP-1 receptor agonists and SGLT-2 inhibitors Study is first to show reduction in autoimmune disease with the common diabetes and obesity drugs Surgical intervention linked to increased lifespan and reduced complications
GLP-1 medications are among the most studied weight loss therapies available
Whilst emerging evidence suggests potential mood benefits, GLP-1 agonists are not without adverse effects, and mental health monitoring remains important during treatment
